In Vivo Effect on Orencia (Abatacept) on the Apoptosis of T Cells, B Cells and Antigen Presenting (APC) Cells in Rheumatoid Arthritis

Trial Profile

In Vivo Effect on Orencia (Abatacept) on the Apoptosis of T Cells, B Cells and Antigen Presenting (APC) Cells in Rheumatoid Arthritis

Withdrawn prior to enrolment
Phase of Trial: Phase IV

Latest Information Update: 23 May 2016

At a glance

  • Drugs Abatacept (Primary) ; Abatacept (Primary) ; Disease-modifying antirheumatics
  • Indications Rheumatoid arthritis
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 09 May 2016 Status changed from not yet recruiting to withdrawn prior to enrolment as the PI has left UCLA and we have not plan to pursue this study.
    • 23 Nov 2012 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top